Skip to main content

Lyell Immunopharma, Inc.

corporate_fare Company Profile

Lyell Immunopharma, Inc.

LYEL·NASDAQ·Life Sciences·CIK 0001806952

We are a late-stage clinical cell therapy company focused on developing next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for cancer patients. Our aim is to fully leverage the curative potential of cell therapy for patients with blood cancers (hematologic malignancies) and solid tumors. We achieve this by creating T-cell therapies designed to produce long-lasting clinical responses. Our CAR T-cell product candidates begin by identifying promising cancer targets. We then engineer a patient's own immune cells with our enhancements, including CAR constructs, technologies, and manufacturing protocols, to give T cells stronger cancer-killing abilities. For blood cancers, we are developing therapies intended to provide significantly better outcomes than currently approved, first-generation CD19 CAR T-cell products. Our main product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is a CAR T-cell therapy that targets both CD19 and CD20. It is designed to increase complete response rates and extend the duration of response compared to approved CD19-targeted CAR T-cell therapies. Ronde-cel uses an 'OR' logic gate to target B cells expressing either CD19 or CD20 with full potency. Its manufacturing process enriches for CD62L-positive cells, creating more naïve and central memory CAR T cells with enhanced stem-like features and anti-tumor activity. We are currently conducting a pivotal single-arm clinical trial (PiNACLE) for ronde-cel in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) receiving third-line or later treatment (3L+). We have also started patient dosing in a Phase 3 randomized controlled head-to-head CAR T-cell therapy trial (PiNACLE-H2H) for LBCL patients receiving second-line treatment (2L), where patients are randomized to receive either ronde-cel or the investigator's choice of axicabtagene ciloleucel (axi-cel) or lisocabtagene maraleucel (liso-cel).

Lyell Immunopharma, Inc. (NASDAQ:LYEL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for LYEL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for LYEL spans 10-Q, 8-K, S-3, 10-K.

Recent high-impact activity:

  • Lyell 10-Q: Q3 Net Loss Widens to $45.5M; $194M Cash Plus $80M Placement
  • Q3 Loss Widens to $45.5M as Lyell Burns Cash Ahead of 2027 Pivotal Data
  • Lyell Prices $80M Private Placement at $10.77/Share, 7.43M Shares
  • $80M Private Placement Funds Ronde-Cel Push Toward BLA Filing
  • Ronde-Cel Shows 77% Complete Response Rate in 3L+ Lymphoma Ahead of ASH

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$36K
Net Income
-$274.45M
Diluted EPS
-$16.06
Op. Cash Flow
-$150.02M
Free Cash Flow
-$150.8M
Operating Income
-$269.4M
Cash & Equivalents
$60.18M
Debt / Equity
0.00×
Net Margin
-7623.56×
Shares Outstanding
21.25M sh
Source: 10-K · filed 2026-03-12 · accession 0001628280-26-017253

Short Interest & Short Volume

10.43 days to cover

FINRA reported short interest of 1,409,625 shares in LYEL as of the October 30, 2026 settlement, a 0.8% increase from the prior period — about 10.4 days to cover at its recent average daily volume. On November 20, 2026, 70.9% of LYEL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,409,625 shares as of October 30, 2026
Change vs prior period▲ 0.8%
Days to cover10.43 at avg daily volume of 135,215
Daily short volume (FINRA facilities)70.9% of 53,756 shares on November 20, 2026
5-day average short volume62.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for LYEL, detected from its recent SEC filings.

2 shelf registrations

Resale Registration for Placement Shares · No Proceeds to Company

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with L →
$13.8
52-week range · as of 2026-11-04 $7.2 – $45
Market cap
$339.28M
Volume
171.1K (0.8× avg)
3-mo avg 227.7K
Live data · 2026-11-21 19:22 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LYEL - Latest Insights

LYEL
Nov 04, 2026, 4:17 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.74
Real-time Price: $13.80 info
Change: -$0.940 (-6%) info
Market Cap: $339.281M info
LYEL
Nov 04, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $15.33
Real-time Price: $13.80 info
Change: -$1.53 (-10%) info
Market Cap: $339.281M info
LYEL
Nov 04, 2026, 9:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.76
Real-time Price: $13.80 info
Change: +$2.04 (+17%) info
Market Cap: $339.281M info
LYEL
Nov 04, 2026, 9:02 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $10.77
Real-time Price: $13.80 info
Change: +$3.03 (+28%) info
Market Cap: $339.281M info
LYEL
Nov 04, 2026, 9:01 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $11.76
Real-time Price: $13.80 info
Change: +$2.04 (+17%) info
Market Cap: $339.281M info
LYEL
May 06, 2026, 4:22 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $20.85
Real-time Price: $13.80 info
Change: -$7.05 (-34%) info
Market Cap: $339.281M info
LYEL
May 06, 2026, 4:14 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $20.85
Real-time Price: $13.80 info
Change: -$7.05 (-34%) info
Market Cap: $339.281M info
LYEL
May 06, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $20.85
Real-time Price: $13.80 info
Change: -$7.05 (-34%) info
Market Cap: $339.281M info
LYEL
Apr 03, 2026, 4:23 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $20.55
Real-time Price: $13.80 info
Change: -$6.75 (-33%) info
Market Cap: $339.281M info
LYEL
Mar 12, 2026, 4:25 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $24.78
Real-time Price: $13.80 info
Change: -$10.97 (-44%) info
Market Cap: $339.281M info
LYEL
Mar 12, 2026, 4:16 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $24.78
Real-time Price: $13.80 info
Change: -$10.97 (-44%) info
Market Cap: $339.281M info
LYEL
Mar 09, 2026, 4:36 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $26.30
Real-time Price: $13.80 info
Change: -$12.50 (-48%) info
Market Cap: $339.281M info
LYEL
Mar 09, 2026, 4:34 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $26.30
Real-time Price: $13.80 info
Change: -$12.50 (-48%) info
Market Cap: $339.281M info
LYEL
Mar 09, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.46
Real-time Price: $13.80 info
Change: -$8.66 (-39%) info
Market Cap: $339.281M info
LYEL
Mar 09, 2026, 8:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $22.46
Real-time Price: $13.80 info
Change: -$8.66 (-39%) info
Market Cap: $339.281M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets